Zhuanzhuan Mu
Beijing, 100730, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.
Journal: BMC medicine
Published: August 18, 2025
Distinctive role of DICER1 mutations in distant metastatic thyroid cancer.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: August 12, 2024
Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Journal: Frontiers in endocrinology
Published: December 12, 2023
AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.
Journal: Neoplasia (New York, N.Y.)
Published: November 06, 2023
Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: October 15, 2023
Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: September 12, 2023
Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 09, 2023
Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
Journal: The Journal of clinical endocrinology and metabolism
Published: March 31, 2023
A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Journal: Frontiers in endocrinology
Published: November 27, 2022
Identification and Validation of a Prognostic Signature Based on Methylation Profiles and Methylation-Driven Gene DAB2 as a Prognostic Biomarker in Differentiated Thyroid Carcinoma.
Journal: Disease markers
Published: June 11, 2022
Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.
Journal: Frontiers in immunology
Published: May 14, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026